Kevin L. Eastwood
Keine laufenden Positionen mehr
Profil
Kevin L.
Eastwood is the founder of eFFECTOR Therapeutics Operations, Inc. (founded in 2012).
He held senior positions in Anadys Pharmaceuticals, Achillion Pharmaceuticals, and Ambrx, Inc. He received his undergraduate degree from Missouri State University.
Ehemalige bekannte Positionen von Kevin L. Eastwood
| Unternehmen | Position | Ende |
|---|---|---|
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Gründer | - |
| AMBRX INC | Corporate Officer/Principal | - |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Corporate Officer/Principal | - |
| ACHILLION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Kevin L. Eastwood
| Missouri State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Health Technology |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Commercial Services |